Bellicum Pharmaceuticals, Inc.
BLCM · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $1 |
| % Growth | – | -100% | -98.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $0 | $1 |
| % Margin | 100% | – | 100% | 100% |
| R&D Expenses | $0 | $5 | $7 | $6 |
| G&A Expenses | $2 | $2 | $1 | $2 |
| SG&A Expenses | $2 | $2 | $1 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $7 | $9 | $8 |
| Operating Income | -$0 | -$7 | -$9 | -$7 |
| % Margin | -0.1% | – | -108,062.5% | -1,468% |
| Other Income/Exp. Net | $0 | -$0 | $1 | $1 |
| Pre-Tax Income | -$1 | -$7 | -$8 | -$6 |
| Tax Expense | $0 | $0 | -$1 | $0 |
| Net Income | -$1 | -$7 | -$7 | -$6 |
| % Margin | -76.3% | – | -93,587.5% | -1,239% |
| EPS | -0.025 | -0.24 | -0.24 | -0.2 |
| % Growth | 89.7% | 0% | -20% | – |
| EPS Diluted | -0.025 | -0.24 | -0.24 | -0.2 |
| Weighted Avg Shares Out | 31 | 31 | 31 | 31 |
| Weighted Avg Shares Out Dil | 31 | 31 | 31 | 31 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | -$1 | -$2 |
| EBITDA | -$0 | -$7 | -$9 | -$7 |
| % Margin | -0.1% | – | -108,062.5% | -1,469.8% |